FrancophonIA/ELRC3.0 huggingface dataset:
English: Overdose with rivastigmine transdermal patches resulting from misuse/dosing errors (application of multiple patches at a time) has been reported in the post-marketing setting.
Spanish: Durante la fase de post-comercialización se ha notificado sobredosis con parches transdérmicos de rivastigmina como resultado del mal uso/errores en la dosificación (administración de múltiples parches al mismo tiempo).
English: Each transdermal patch consists of three layers; a backing layer, an adhesive layer containing the medicine and a transparent, split release liner.
Spanish: Cada parche se compone de 3 capas: una capa externa, una capa adhesiva que contiene el medicamento y una lámina protectora transparente formada por dos hojas.
English: Your doctor will tell you which Rivastigmine 3M Health Care Ltd. transdermal patch is most suitable for you.
Spanish: Su médico le indicará la dosis de Rivastigmina 3M Health Care Ltd. parche transdérmico más adecuada en su caso.
English: - The other ingredients are polyester, ethyl vinyl acetate, acrylate copolymer adhesive and isopropyl myristate.
Spanish: - Los demás componentes son poliéster, acetato de etilvinilo, adhesivo de copolímero de acrilato y miristato de isopropilo.
English: LIST OF EXCIPIENTS Also contains polyester, ethyl vinyl acetate, acrylate copolymer adhesive and isopropyl myristate.
Spanish: También contiene poliéster, acetato de etilvinilo, adhesivo de copolímero de acrilato y miristato de isopropilo.
English: - if you have, or have ever had, seizures.
Spanish: - si tiene o ha tenido alguna vez convulsiones.
English: - if you have impaired liver function.
Spanish: - si tiene problemas del hígado (insuficiencia hepática).
English: - if you have, or have ever had, difficulties in passing urine.
Spanish: - si tiene o ha tenido alguna vez dificultades al orinar.
English: Renal and urinary disorders Common General disorders and administration site conditions Common
Spanish: Incontinencia urinaria Trastornos generales y alteraciones en el lugar de administración Frecuentes
English: Table 1
Spanish: Tabla 1
English: Slow heartbeat and fainting may also occur.
Spanish: También puede producirse un enlentecimiento de la frecuencia cardiaca y desmayos.
English: The active substance of Rivastigmine 3M Health Care Ltd. is rivastigmine.
Spanish: El principio activo de Rivastigmina 3M Health Care Ltd. es rivastigmina.
English: Rivastigmine 13.3 mg/24 h
Spanish: Rivastigmina 13,3 mg/24 h
English: Otherwise treatment should be re-initiated with 4.6 mg/24 h.
Spanish: En caso contrario, el tratamiento debe iniciarse con 4,6 mg/24 h.
English: Each patch is sealed in a pouch that protects it until you are ready to put it on. Do not open the pouch or remove a patch until just before you apply it.
Spanish: Cada parche se encuentra en un sobre que lo protege hasta que se lo vaya a poner.
English: Psychiatric disorders Common
Spanish: Poco frecuentes Trastornos psiquiátricos Frecuentes
English: - Carefully remove any existing patch before putting on a new one.
Spanish: - Quítese cuidadosamente cualquier parche que lleve antes de ponerse uno nuevo.
English: - Hepatic impairment: Patients with clinically significant hepatic impairment might experience more adverse reactions (see sections 4.2 and 5.2).
Spanish: - Insuficiencia hepática: Los pacientes con insuficiencia hepática clínicamente significativa pueden experimentar más reacciones adversas (ver secciones 4.2. y 5.2.).
English: Concomitant administration of rivastigmine with commonly prescribed medicinal products, such as antacids, antiemetics, antidiabetics, centrally acting antihypertensives, beta blockers, calcium channel blockers, inotropic agents, antianginals, non-steroidal anti-inflammatory agents, oestrogens, analgesics, benzodiazepines and antihistamines, was not associated with an alteration in the kinetics of rivastigmine or an increased risk of clinically relevant untoward effects.
Spanish: No se detectaron alteraciones en la farmacocinética de la rivastigmina ni un aumento del riesgo de sus efectos adversos clínicamente significativos tras la administración concomitante de rivastigmina con medicamentos recetados frecuentemente, tales como antiácidos, antieméticos, antihipertensivos de acción central, betabloqueantes, bloqueantes de los canales de calcio, agentes inotrópicos, antianginosos, antiinflamatorios no esteroideos, estrógenos, analgésicos, benzodiazepinas y antihistamínicos.
English: - Renal impairment: Patients with clinically significant renal impairment might experience more adverse reactions (see sections 4.2 and 5.2).
Spanish: - Insuficiencia renal: Los pacientes con insuficiencia renal clínicamente significativa pueden experimentar más reacciones adversas (ver secciones 4.2. y 5.2.).
English: Table 4
Spanish: Tabla 4
English: The backing layer is transparent to translucent and labelled with “R5” (Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch) or “R10” (Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch).
Spanish: La capa externa es de transparente a translúcida y está marcada con “R5” (Rivastigmina 3M Health Care Ltd. 4,6 mg/24 h parche transdérmico) o “R10” (Rivastigmina 3M Health Care Ltd. 9,5 mg/24 h parche transdérmico).
English: Hands should be washed with soap and water after removing the patch.
Spanish: Después de retirar el parche las manos se deben lavar con jabón y agua.
English: What you need to know before you use Rivastigmine 3M Health Care Ltd.
Spanish: Qué necesita saber antes de empezar a usar Rivastigmina 3M Health Care Ltd.
English: Polyester and ethyl vinyl acetate
Spanish: Lámina externa: - Poliéster y acetato de etilvinilo
English: ADCS-IADL scores: A positive difference in DLSM indicates greater improvement in Rivastigmine 13.3 mg/24 h as compared to Rivastigmine 9.5 mg/24 h.
Spanish: Puntuaciones ADCS-AIDL: Una diferencia negativa en DLSM indica una mejoría mayor en Rivastigmina 13,3 mg/24 h comparado con Rivastigmina 9,5 mg/24 h.
English: There is no relevant use of Rivastigmine 3M Health Care Ltd. in the paediatric population in the treatment of Alzheimer's disease.
Spanish: Rivastigmina 3M Health Care Ltd. no debe utilizarse en la población pediátrica en el tratamiento de la enfermedad de Alzheimer.
English: Compared to a patient with a body weight of 65 kg, the rivastigmine steady-state concentrations in a patient with a body weight of 35 kg would be approximately doubled, while for a patient with a body weight of 100 kg the concentrations would be approximately halved.
Spanish: En comparación con un paciente de 65 kg de peso, las concentraciones de rivastigmina en estado estacionario aproximadamente se duplicarían en un paciente de 35 kg y se reducirían a la mitad en uno de 100 kg. Debido al marcado efecto del peso corporal en la exposición al principio activo, se recomienda una especial atención al ajuste de dosis (escalada) en pacientes con peso corporal muy bajo (ver sección 4.4.)
English: The percentages decreased in both rivastigmine 13.3 mg/24 h transdermal patch and rivastigmine 9.5 mg/24 h transdermal patch treatment groups over time (>24 weeks): application site erythema (0.8% vs. 1.6%) and application site pruritus (0.4% vs. 1.2%), respectively.
Spanish: Los porcentajes disminuyeron en ambos grupos de tratamiento con rivastigmina 13,3 mg/24 h parches transdérmicos y rivastigmina 9,5 mg/24 h. parches transdérmicos con el tiempo (>24 semanas): eritema en el lugar de la administración (0,8% frente a 1,6%) y prurito en el lugar de la administración (0,4% frente a 1,2%), respectivamente.
English: Application site skin reactions (e.g. application site erythema, application site pruritus, application site oedema, application site dermatitis, application site irritation), asthenic conditions (e.g. fatigue,
Spanish: Reacciones cutáneas en el lugar de administración (p. ej. eritema prurito, edema, dermatitis, irritación), estados de astenia (p. ej. fatiga, astenia), pirexia, disminución de peso
English: ADCS-CGIC
Spanish: Puntuaciones ADCS-CGIC <4
English: No study was conducted with rivastigmine transdermal patches in subjects with hepatic impairment.
Spanish: No se han llevado a cabo ensayos con parches transdérmicos de rivastigmina en personas con insuficiencia hepática.
English: • Take off the previous patch before putting ONE new patch on.
Spanish: • Quítese el parche anterior antes de ponerse UN parche nuevo.
English: - Fast or uneven heartbeat - High blood pressure - Fits (seizures) - Liver disorders (yellow skin, yellowing of the whites of the eyes, abnormal darkening of the urine or unexplained nausea, vomiting, tiredness and loss of appetite) - Changes in tests which show how well the liver is working - Feeling restless
Spanish: Trastornos hepáticos (coloración amarillenta de la piel, amarilleamiento del blanco de los ojos, oscurecimiento anormal de la orina o náuseas inexplicables, vómitos, cansancio y pérdida de apetito)
English: Table 3
Spanish: Tabla 3
English: Table 2
Spanish: Tabla 2
English: - Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patches: Each patch releases 9.5 mg of rivastigmine per 24 hours, is 8.3 cm2 and contains 14.33 mg of rivastigmine.
Spanish: Rivastigmina 3M Health Care Ltd. 9,5 mg/24 h parche transdérmico EFG: Cada parche libera 9,5 mg de rivastigmina en 24 h, mide 8,3 cm2 y contiene 14,33 mg de rivastigmina.
English: - The patch should be pressed down firmly for at least 30 seconds using the palm of the hand until the edges stick well.
Spanish: - El parche debe aplicarse presionando firmemente contra la piel con la palma de la mano durante un mínimo de 30 segundos hasta que los bordes estén bien pegados.
English: The most commonly reported skin irritation events during the first 24 weeks of the double-blind period with rivastigmine 13.3 mg/24 h transdermal patches and rivastigmine 9.5 mg/24 h transdermal patches, respectively were application site erythema (5.7% vs 4.6%) and application site pruritus (3.6% vs 2.8%).
Spanish: Los casos de irritación cutánea que fueron notificados más frecuentemente durante las primeras 24 semanas del periodo doble ciego con rivastigmina 13,3 mg/24 h parches transdérmicos y rivastigmina 9,5 mg/24 h parches transdérmicos fueron, respectivamente, eritema en el lugar de administración (5,7% frente a 4,6%) y prurito en el lugar administración (3,6% frente a 2,8%).
English: DB-week 48 Value Change 264 4.1 268 4.9 -0.8 (-2.1,
Spanish: Cambio 264 4,1 268 4,9 -0,8 (-2,1, 0,5) 0,227
English: No study was conducted with rivastigmine transdermal patches in subjects with renal impairment.
Spanish: No se han llevado a cabo ensayos con parches transdérmicos de rivastigmina en personas con insuficiencia renal.
English: - Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patches: Each patch releases 4.6 mg of rivastigmine per 24 hours, is 4.15 cm2 and contains 7.17 mg of rivastigmine.
Spanish: Rivastigmina 3M Health Care Ltd. 4,6 mg/24 h parche transdérmico EFG: Cada parche libera 4,6 mg de rivastigmina en 24 h, mide 4,15 cm2 y contiene 7,17 mg de rivastigmina.
English: Keep out of the sight and reach of children.
Spanish: FUERA DE LA VISTA Y DEL ALCANCE DE LOS NIÑOS Mantener fuera de la vista y del alcance de los niños.
English: Pruritus, erythema, urticaria, vesicles, allergic dermatitis, disseminated
Spanish: Prurito, eritema, urticaria, ampollas, dermatitis alérgica, reacciones de hipersensibilidad diseminadas de la piel
English: SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Spanish: ADVERTENCIA ESPECIAL DE QUE EL MEDICAMENTO DEBE MANTENERSE
English: - Then press the patch firmly in place for at least 30 seconds using the palm of the hand to make sure that the edges stick well.
Spanish: - Presione firmemente el parche contra la piel con la palma de la mano durante un mínimo de 30 segundos y asegúrese de que los bordes se han pegado bien.
English: IMPORTANT: - Take off the previous patch before putting ONE new patch on. - Only one patch per day.
Spanish: IMPORTANTE: - Quítese el parche anterior antes de ponerse UN parche nuevo.
English: Fall
Spanish: CAD
English: Do not apply a new patch to the same skin area twice within 14 days.
Spanish: Espere al menos 14 días para volver a ponerse un parche nuevo exactamente en la misma área de piel.
English: OTHER Apply one patch per day.
Spanish: - Sólo un parche al día.
English: STATEMENT OF ACTIVE SUBSTANCE(S) 1 transdermal patch of 8.3 cm2 contains 14.33 mg rivastigmine and delivers 9.5 mg/24 h.
Spanish: 1 parche transdérmico de 8,3 cm2 contiene 14,33 mg de rivastigmina y libera 9,5 mg/24 h.
English: STATEMENT OF ACTIVE SUBSTANCE(S) 1 transdermal patch of 4.15 cm2 contains 7.17 mg rivastigmine and delivers 4.6 mg/24 h.
Spanish: 1 parche transdérmico de 4,15 cm2 contiene 7,17 mg de rivastigmina y libera 4,6 mg/24 h.
English: What Rivastigmine 3M Health Care Ltd. looks like and contents of the pack The transdermal patches are rectangular with rounded corners, approximately 2.5 cm by 1.8 cm (Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch) or 3.5 cm by 2.6 cm (Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch).
Spanish: Los parches transdérmicos son rectangulares con las esquinas redondeadas, de aproximadamente 2,5 cm por 1,8 cm (Rivastigmina 3M Health Care Ltd. 4,6 mg/24 h parche transdérmico) o 3,5 cm por 2,6 cm (Rivastigmina 3M Health Care Ltd. 9,5 mg/24 h parche transdérmico).
English: What Rivastigmine 3M Health Care Ltd. contains - The active substance is rivastigmine.
Spanish: Composición de Rivastigmina 3M Health Care Ltd. - El principio activo es rivastigmina.
English: INFORMATION IN BRAILLE Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h
Spanish: INFORMACIÓN EN BRAILLE Rivastigmina 3M Health Care Ltd. 4,6 mg/24 h
English: If you are pregnant, the benefits of using Rivastigmine 3M Health Care Ltd. transdermal patches must be assessed against the possible effects on your unborn child. Rivastigmine 3M Health Care Ltd. should not be used during pregnancy unless clearly necessary.
Spanish: Si está embarazada, es necesario evaluar los beneficios del uso de Rivastigmina 3M Health Care Ltd. parches transdérmicos frente a los posibles efectos adversos para el feto.
English: Very rare (may affect up to 1 in 10,000 people) - High blood pressure - Inflammation of the pancreas - the signs include serious upper stomach pain, often with feeling sick (nausea) or being sick (vomiting) - Bleeding in the gut - shows as blood in stools or when being sick - Seeing things that are not there (hallucinations) - Some people who have been violently sick have had tearing of the tube that connects your mouth with your stomach (oesophagus)
Spanish: Inflamación del páncreas - los signos incluyen dolor fuerte en la parte alta del estómago, a menudo con sensación de mareo (náuseas) o vómitos Sangrado gastrointestinal - se manifiesta como sangre en las heces o al vomitar Ver cosas que no existen (alucinaciones)
English: If you forget to use Rivastigmine 3M Health Care Ltd.
Spanish: Si olvidó usar Rivastigmina 3M Health Care Ltd.
English: INFORMATION IN BRAILLE Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h
Spanish: INFORMACIÓN EN BRAILLE Rivastigmina 3M Health Care Ltd. 9,5 mg/24 h
English: Uncommon (may affect up to 1 in 100 people) - Problems with your heartbeat such as slow heartbeat - Seeing things that are not really there (hallucinations) - Stomach ulcer - Dehydration (losing too much fluid) - Hyperactivity (high level of activity, restlessness) - Aggression
Spanish: Poco frecuentes (pueden afectar hasta a 1 de cada 100 personas) Problemas con el ritmo de su corazón tales como ritmo cardiaco lento Ver cosas que realmente no existen (alucinaciones) Úlcera de estómago
English: EU/1/14/911/005 [7 pouches] EU/1/14/911/006 [30 pouches] EU/1/14/911/007 [60 pouches] EU/1/14/911/008 [90 pouches]
Spanish: EU/1/14/911/005 [7 sobres] EU/1/14/911/006 [30 sobres] EU/1/14/911/007 [60 sobres] EU/1/14/911/008 [90 sobres]
English: Mean change at week 24  SD -0.6  6.4 p-value versus placebo
Spanish: Media basal  DE Cambio medio a las 24 semanas 24  DE Valor p versus placebo ADCS-CGIC
English: EU/1/14/911/001 [7 pouches] EU/1/14/911/002 [30 pouches] EU/1/14/911/003 [60 pouches] EU/1/14/911/004 [90 pouches]
Spanish: EU/1/14/911/001 [7 sobres] EU/1/14/911/002 [30 sobres] EU/1/14/911/003 [60 sobres] EU/1/14/911/004 [90 sobres]
English: Take off the previous patch before putting ONE new patch on.
Spanish: Quítese el parche anterior antes de ponerse UN parche nuevo.
English: Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Spanish: Uso de Rivastigmina 3M Health Care Ltd. con otros medicamentos Informe a su médico o farmacéutico si está utilizando, ha utilizado recientemente o podría tener que utilizar cualquier otro medicamento.
English: How to use Rivastigmine 3M Health Care Ltd.
Spanish: Cómo usar Rivastigmina 3M Health Care Ltd.
English: ITT: Intent-To-Treat; LOCF: Last Observation Carried Forward 1 Based on ANCOVA with treatment and country as factors and baseline value as a covariate.
Spanish: Media basal  DE Cambio medio a las 24 semanas 24  DE Valor p versus placebo * p≤0,05 versus placebo ITT: intención de tratar; LOCF: traslación de los datos de la última observación disponible 1 ANCOVA con tratamiento y país como factores y el valor basal como covariable.
English: - Treatment usually starts with Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h. - The recommended daily dose is Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h. If well tolerated, the treating physician may consider increasing the dose to 13.3 mg/24 h (this high strength is currently not available from 3M but may be available from other Marketing
Spanish: - Normalmente se comienza el tratamiento con Rivastigmina 3M Health Care Ltd. 4,6 mg/24 h. - La dosis diaria habitual recomendada es Rivastigmina 3M Health Care Ltd. 9,5 mg/24 h. - Lleve sólo un parche de Rivastigmina 3M Health Care Ltd. al mismo tiempo y sustituya el parche por otro nuevo a las 24 horas.
English: - Press the patch firmly in place for at least 30 seconds using the palm of the hand.
Spanish: - Presione firmemente el parche contra la piel con la palma de la mano durante un mínimo de 30 segundos.
English: Cardiac disorders Uncommon Not known
Spanish: Trastornos vasculares No conocida
English: You should not breast-feed during treatment with Rivastigmine 3M Health Care Ltd. transdermal patches.
Spanish: No deberá dar el pecho durante el tratamiento con Rivastigmina 3M Health Care Ltd..
English: Dehydration
Spanish: Hipertensión
English: A relationship between active substance exposure at steady state (rivastigmine and metabolite
Spanish: Se ha observado en pacientes con demencia de Alzheimer una relación entre la exposición al principio activo en el estado estacionario (rivastigmina y metabolito NAP226-90) y el peso corporal.
English: Transdermal patches
Spanish: Síntomas extrapiramidales
English: Package Leaflet: Information for the user Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch rivastigmine
Spanish: Rivastigmina 3M Health Care Ltd. 4,6 mg/24 h parche transdérmico EFG Rivastigmina 3M Health Care Ltd. 9,5 mg/24 h parche transdérmico EFG
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch rivastigmine
Spanish: NOMBRE DEL MEDICAMENTO Y VÍA(S) DE ADMINISTRACIÓN Rivastigmina 3M Health Care Ltd. 9,5 mg/24 h parche transdérmico EFG rivastigmina Vía transdérmica.
English: Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch rivastigmine
Spanish: Rivastigmina 3M Health Care Ltd. 4,6 mg/24 h parche transdérmico EFG rivastigmina
English: Switching from capsules or oral solution to transdermal patches Based on comparable exposure between oral and transdermal rivastigmine (see section 5.2), patients treated with rivastigmine capsules or oral solution can be switched to Rivastigmine 3M Health Care Ltd. transdermal patches as follows: - A patient on a dose of 3 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches.
Spanish: ), los pacientes en tratamiento con cápsulas o solución oral de rivastigmina pueden cambiarse a Rivastigmina 3M Health Care Ltd. parches transdérmicos como se indica a continuación: - Un paciente con una dosis oral de 3 mg/día de rivastigmina puede cambiarse a parches transdérmicos de 4,6 mg/24 h. - Un paciente con una dosis oral de 6 mg/día de rivastigmina puede cambiarse a parches transdérmicos de 4,6 mg/24 h. - Un paciente con una dosis oral estable y bien tolerada de 9 mg/día de rivastigmina puede cambiarse a parches transdérmicos de 9,5 mg/24 h. Si la dosis oral de 9 mg/día no ha sido estable y bien tolerada, se recomienda cambiar a parches transdérmicos de 4,6 mg/24 h. - Un paciente con una dosis oral de 12 mg/día de rivastigmina puede cambiarse a parches transdérmicos de 9,5 mg/24 h.
English: NAME OF THE MEDICINAL PRODUCT Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch
Spanish: NOMBRE DEL MEDICAMENTO Rivastigmina 3M Health Care Ltd. 9,5 mg/24 h parche transdérmico EFG
English: Take off your patch and tell your doctor straight away, if you notice any of the side effects above.
Spanish: Si nota alguno de los efectos adversos listados arriba, quítese el parche e informe inmediatamente a su médico.
English: NAME OF THE MEDICINAL PRODUCT Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch
Spanish: NOMBRE DEL MEDICAMENTO Rivastigmina 3M Health Care Ltd. 4,6 mg/24 h parche transdérmico EFG
English: Isopropyl myristate
Spanish: Úlcera gástrica
English: Take off your patch and tell your doctor straight away, if you notice any of the following side effects which could become serious:
Spanish: Si advierte alguno de los siguientes efectos adversos, que pueden ser graves, quítese el parche e informe inmediatamente a su médico.
English: This leaflet was last revised in {month YYYY}
Spanish: Fecha de la última revisión del prospecto:
English: How to store Rivastigmine 3M Health Care Ltd.
Spanish: Conservación de Rivastigmina 3M Health Care Ltd.
English: Common (may affect up to 1 in 10 people) - Loss of appetite - Feeling dizzy - Feeling agitated or sleepy - Urinary incontinence (inability to retain adequate urine)
Spanish: Sensación de agitación o adormecimiento Incontinencia urinaria (imposibilidad de detener adecuadamente la orina).
English: Rivastigmine 9.5 mg/24 h n Mean n Mean DLSM 95% CI p-value
Spanish: Rivastigmina 9,5 mg/24 h n Media n Media DLS M
English: The patient's weight should be monitored during therapy with Rivastigmine 3M Health Care Ltd. transdermal patches.
Spanish: Durante el tratamiento con Rivastigmina 3M Health Care Ltd. parches transdérmicos debe monitorizarse el peso del paciente.
English: - A patient on a dose of 12 mg/day oral rivastigmine can be switched to 9.5 mg/24 h transdermal patches.
Spanish: Pacientes con una respuesta clínicamente significativa (%) Rivastigmina parches transdérmicos 9,5 mg/24 h
English: Backing layer
Spanish: Lámina de liberación: - Poliéster
English: transdermal patches 9.5 mg/24 h
Spanish: Rivastigmina parches transdérmicos 9,5 mg/24 h N = 251
English: If you stop using Rivastigmine 3M Health Care Ltd. Tell your doctor or pharmacist if you stop using the patch.
Spanish: Informe a su médico o farmacéutico si deja de utilizar los parches.
English: PHARMACEUTICAL FORM AND CONTENTS
Spanish: Aspecto del producto y contenido del envase
English: • Press the patch firmly in place for at least 30 seconds using the palm of the hand.
Spanish: • Presione firmemente el parche contra la piel con la palma de la mano durante un mínimo de
English: Breast-feeding
Spanish: Bradicardia
English: NAME OF THE MEDICINAL PRODUCT Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch rivastigmine
Spanish: Rivastigmina 3M Health Care Ltd.9,5 mg/24 h parche transdérmico EFG rivastigmina
English: This summary was last updated in 04-2016.
Spanish: Fecha de la última actualización del presente resumen: 04-2016.
English: The medicine can only be obtained with a prescription.
Spanish: Este medicamento solo se podrá dispensar con receta médica.